表皮生长因子（EGF）自1980年代末以来一直被用于伤口管理和再生医学。由于其出色的耐受性和疗效，EGF已经被广泛使用长时间。EGF在组织工程，癌症治疗，肺部疾病，胃溃疡和伤口愈合中有许多应用。然而，它在体内和储存期间的稳定性是一个主要问题。本次回顾重点介绍了EGF的局部使用，特别是慢性伤口愈合，以及生物材料输送EGF的新兴用途和未来的研究可能性。为了成功地将EGF输送到伤口，需要一个长期抗蛋白酶剪切和稳定性的输送系统。生物材料是开发这种系统的研究领域。这些系统可以用于非愈合性伤口，如糖尿病足溃疡，压力性溃疡和烧伤。在这些病理情况中，EGF可以减少下肢截肢的风险，因为它可以加速伤口愈合过程。此外，适当的输送系统也可以在伤口中稳定和控制EGF的释放。已经有几项体外和体内的研究证明了这些系统在上述类型的伤口中的疗效。此外，已经有几种制剂，如软膏和局部注射，已经在市场上销售。然而，这些产品在EGF的扩散不足，生物利用度低，存储条件和保质期方面仍存在问题。本文讨论了由注入EGF的生物材料制成的纳米配方，这可能是未来治愈慢性伤口的有望输送系统。© 2023. 韩国药学协会。

Epidermal growth factor (EGF) has been used in wound management and regenerative medicine since the late 1980s. It has been widely utilized for a long time and still is because of its excellent tolerability and efficacy. EGF has many applications in tissue engineering, cancer therapy, lung diseases, gastric ulcers, and wound healing. Nevertheless, its in vivo and during storage stability is a primary concern. This review focuses on the topical use of EGF, especially in chronic wound healing, the emerging use of biomaterials to deliver it, and future research possibilities. To successfully deliver EGF to wounds, a delivery system that is proteolytically resistant and stable over the long term is required. Biomaterials are an area of interest for the development of such systems. These systems may be used in non-healing wounds such as diabetic foot ulcers, pressure ulcers, and burns. In these pathologies, EGF can reduce the risk of amputation of the lower extremities, as it accelerates the wound healing process. Furthermore, appropriate delivery system would also stabilize and control the EGF release profile in a wound. Several in vitro and in vivo studies have already proven the efficacy of such systems in the above-mentioned types of wounds. Moreover, several formulations such as ointments and intralesional injections are already available on the market. However, these products are still problematic in terms of inadequate diffusion of EGF, low bioavailability storage conditions, and shelf-life. This review discusses the nano formulations comprising biomaterials infused with EGF which could be a promising delivery system for chronic wound healing in the future.© 2023. The Pharmaceutical Society of Korea.